Suppression of renal fibrosis by galectin-1 in high glucose-treated renal epithelial cells

Experimental Cell Research

Volumn 316, Issue 19, 2010, Pages 3282-3291

  Okano, Kazuhiro ^a   Tsuruta, Yuki ^a   Yamashita, Tetsuri ^a   Takano, Mari ^a   Echida, Yoshihisa ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetes; Galectin 1; Mitogen activated protein kinase; Renal fibrosis; Smad3; TGF 1

Indexed keywords

COLLAGEN TYPE 1; GALECTIN 1; GLUCOSE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; ALPHA 2(I) COLLAGEN; COLLAGEN; SMAD3 PROTEIN, HUMAN;

ARTICLE; EPITHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETIC TRANSCRIPTION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT;

CELL LINE; COLLAGEN; COLLAGEN TYPE I; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; GALECTIN 1; GLUCOSE; HUMANS; KIDNEY; MATRIX METALLOPROTEINASE 1; MODELS, BIOLOGICAL; PROTEIN TRANSPORT; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC;

EID: 77958085251     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.08.015     Document Type: Article

References (36)

1. US Renal Data System USRDS 2004 annual data report. Am. J. Kidney Dis. 2005, 45:8-280.
2. Adler S. Structure-function relationships associated with extracellular matrix alteration in diabetic glomerulopathy. J. Am. Soc. Nephrol. 1994, 5:1165-1172.
3. Nakao A., Imamura T., Souchelnyskyi S., Kawabata M., Ishisaki A., Oeda E., Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P. TGF-beta receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO J. 1997, 16:5353-5362.
4. Li J.H., Huang X.R., Zhu H.J., Johnson R., Lan H.Y. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003, 63:2010-2019.
5. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-b antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
6. Ostalska-Nowicka D., Zachwieja J., Nowicki M., Kaczmarek E., Siwinska A., Witt M. Immunohistochemical detection of galectin-1 in renal biopsy specimens of children and its possible role in proteinuric glomerulopathies. Histopathology 2007, 51:468-476.
7. Burger A., Filsinger S., Cooper D.N., Hansch G.M. Expression of the 14kDa galactose-binding protein, galectin-1, on human tubular epithelial cells. Kidney Int. 1996, 50:754-759.
8. Tsuchiyama Y., Wada J., Zhang H., Morita Y., Hiragushi K., Hida K., Shikata K., Yamamura M., Kanwar Y.S., Makino H. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wister Kyoto rats. Kidney Int. 2000, 58:1941-1952.
9. Perone M.J., Bertera S., Shufesky W.J., Divito S.J., Montecalvo A., Mathers A.R., Larregina A.T., Pang M., Seth N., Wucherpfennig K.W., Trucco M., Baum L.G., Morelli A.E. Suppression of autoimmune diabetes by soluble galectin-1. J. Immunol. 2009, 182:2641-2653.
10. Camby I., Le Mercier M., Lefranc F., Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16:137R-157R.
11. Paz A., Haklai R., Elad G., Ballan E., Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2000, 20:7486-7493.
12. Elad-Sfadia G., Haklai R., Ballan E., Gabius H.J., Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J. Biol. Chem. 2002, 277:37169-37175.
13. Baum L.G., Blackall D.P., Arias-Magallano S., Nanigian D., Uh S.Y., Browne J.M., Hoffmann D., Emmanouilides C.E., Territo M.C., Baldwin G.C. Amelioration of graft versus host disease by galectin-1. Clin. Immunol. 2003, 109:295-307.
14. Okano K., Uchida K., Nitta K., Hayashida T. Galectin-1 suppresses alpha2(I) collagen through Smad3 in renal epithelial cells. Cell. Mol. Life Sci. 2008, 65:3304-3311.
15. Racusen L.C., Monteil C., Sgrignoli A., Lucskay M., Marouillat S., Rhim J.G., Morin J.P. Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J. Lab. Clin. Med. 1997, 129:318-329.
16. Zawal L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., Kern S.E. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998, 1:1611-1617.
17. Benanti J.A., Williams D.K., Robinson K.L., Ozer H.L., Galloway D.A. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol. Cell. Biol. 2002, 22:7385-7397.
18. Poncelet A.C., De Caestecker M.P., Schnaper H.W. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int. 1999, 56:1354-1365.
19. Xiao H., Wu Z., Shen H., Luo A.L., Yang Y.F., Li X.B., Zhu D.Y. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of Stealth™ RNAi. Basic Clin. Pharmacol. Toxicol. 2008, 103:342-348.
20. Hayashida T., Schnaper H.W. High ambient glucose enhances sensitivity to TGF-β1 via extracellular signal-regulated kinase and protein kinase Cδ activates in human mesangial cells. J. Am. Soc. Nephrol. 2004, 15:2032-2041.
21. Deng W.G., Zhu Y., Montero A., Wu K.K. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal. Biochem. 2003, 323:12-18.
22. Perone M.J., Bertera S., Shufesky W.J., Divoto S.J., Montecalvo A., Mathers A.R., Larregina A.T., Pang M., Seth N., Wucherpfennig K.W., Trucco M., Baum L.G., Morelli A.E. Suppression of autoimmune diabetes by soluble galectin-1. J. Immunol. 2009, 182:2641-2653.
23. Shimizu M., Khoshnoodi J., Akimoto Y., Kawakami H., Hirano H., Higashihara E., Hosoyamada M., Sekine Y., Kurayama R., Joh K., Hirabayashi J., Kasai K., Tryggvason K., Ito N., Yan K. Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephritic syndrome. Lab. Invest. 2009, 89:178-195.
24. Daroqui C.M., Ilarregui J.M., Rubinstein N., Salatino M., Toscano M.A., Vazquez P., Bakin A., Puricelli L., de Kier Joffe E.B., Rabinovich G.A. Regulation of galectin-1 expression by transforming growth factor b1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol. Immunother. 2007, 56:491-499.
25. de Caestecker M.P., Peik E., Roberts A.B. Role of transforming growth factor-β signaling in cancer. J. Natl Cancer Inst. 2000, 92:1388-1402.
26. Awazu M., Ishikura K., Hida M., Hoshiya M. Mechanisms of mitogen-activated protein kinase cascade is activated in glomeruli of diabetes. J. Am. Soc. Nephrol. 1999, 10:738-745.
27. Scott K., Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj. J. 2004, 19:467-477.
28. Moses H.L., Yang E.Y., Pietenpol J.A. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990, 63:245-247.
29. Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S. Large-scale identification and characterization of human genes that activate NF-kB and MAPK signaling pathways. Oncogene 2003, 22:3307-3318.
30. van der Leij J., van den Berg A., Blokzijl T., Harms G., van Goor H., Zwiers P., van Weeghel R., Poppema S., Visser L. Dimeric galectin-1 induces IL-10 production in T-lymphocytes; an important tool in the regulation of the immune response. J. Pathol. 2004, 204:511-518.
31. Nishida M., Okumura Y., Sato H., Hamaoka K. Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. Nephrol. Dial. Transplant. 2008, 23:2520-2524.
32. Rand L., Green J.A., Saraiva L., Friedland J.S., Elkington P.T. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade. J. Immunol. 2009, 182:5865-5872.
33. Noh E.M., Kim J.S., Hur H., Park B.H., Song E.K., Han M.K., Kwon K.B., Yoo W.H., Shim I.K., Lee S.J., Youn H.J., Lee Y.R. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology 2009, 48:45-48.
34. Oner C., Schatz F., Kizilay G., Murk W., Buchwalder L.F., Kayisli U.A., Arici A., Lockwood C.J. Progression-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells. J. Clin. Endocrinol. Metab. 2008, 93:252-259.
35. Oh S.M., Hahm D.H., Kim I.H., Choi S.Y. Human neutrophil lactoferrin trans-activates the matrix metalloproteinase 1 gene through stress-activated MAPK signaling modules. J. Biol. Chem. 2001, 276:42575-42579.
36. Cosqrove D., Meehan D.T., Delimont D., Pozzi A., Chen X., Rodgers K.D., Tempero R.M., Zallocchi M., Rao V.H. Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndrome. Am. J. Pathol. 2008, 172:761-773.